{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Polyoma+Virus+Nephropathy", "query": { "condition": "Polyoma Virus Nephropathy" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 36, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Polyoma+Virus+Nephropathy&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T22:55:49.143Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07115043", "title": "A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma (Skin)", "Renal Cell Carcinoma", "Merkel Cell Carcinoma", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Gastric Cancer/Gastroesophageal Junction Cancer", "High Grade Serous Ovarian Carcinoma" ], "interventions": [ { "name": "AZD6750", "type": "DRUG" }, { "name": "rilvegostomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-07-29", "completion_date": "2029-10-02", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-07-22T22:55:49.143Z", "location_count": 6, "location_summary": "Grand Rapids, Michigan • St Louis, Missouri • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07115043" }, { "nct_id": "NCT03126110", "title": "Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "INCAGN01876", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2017-04-25", "completion_date": "2021-11-09", "has_results": true, "last_update_posted_date": "2025-08-14", "last_synced_at": "2026-07-22T22:55:49.143Z", "location_count": 15, "location_summary": "Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03126110" }, { "nct_id": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "FT538", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Monoclonal antibody - Dose Escalation", "type": "COMBINATION_PRODUCT" }, { "name": "Monoclonal antibody - Dose Expansion", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-10-15", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-07-22T22:55:49.143Z", "location_count": 4, "location_summary": "Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05069935" }, { "nct_id": "NCT03629756", "title": "A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Breast Cancer", "Colorectal Cancer", "Melanoma", "Bladder Cancer", "Ovarian Cancer", "Endometrial Cancer", "Merkel Cell Carcinoma", "GastroEsophageal Cancer", "Renal Cell Carcinoma", "Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "Etrumadenant", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2018-07-24", "completion_date": "2021-09-03", "has_results": false, "last_update_posted_date": "2024-05-24", "last_synced_at": "2026-07-22T22:55:49.143Z", "location_count": 12, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03629756" }, { "nct_id": "NCT03277352", "title": "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignancies", "Metastatic Cancer" ], "interventions": [ { "name": "INCAGN01876", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Biosciences International Sàrl", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2017-11-21", "completion_date": "2020-07-01", "has_results": true, "last_update_posted_date": "2021-07-22", "last_synced_at": "2026-07-22T22:55:49.143Z", "location_count": 2, "location_summary": "Los Angeles, California • Hackensack, New Jersey", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03277352" }, { "nct_id": "NCT04670445", "title": "Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stage IV Melanoma", "Advanced Lung Cancer", "Stage IV Non-Small Cell Lung Cancer", "Unresectable Non-Small Cell Lung Carcinoma", "Unresectable Stage III Non-Small Cell Lung Cancer", "Small Cell Lung Cancer Extensive Stage", "Stage IV Merkel Cell Carcinoma", "Stage IV Cutaneous Squamous Cell Carcinoma", "Stage IV Basal Cell Carcinoma", "Stage IV Breast Cancer", "Stage IV Colorectal Cancer", "Stage IV Gastric Cancer", "Stage IV Esophageal Cancer", "Stage IV Hepatocellular Cancer", "Stage IV Renal Cell Carcinoma", "Stage IV Bladder Cancer", "Stage IV Head and Neck Squamous Cell Carcinoma", "Stage IV Cervical Cancer", "Stage IV Endometrial Cancer", "Stage IV Mesothelioma", "Immunotherapy", "Immune Checkpoint Inhibitors" ], "interventions": [ { "name": "Educational Video and QPL List", "type": "OTHER" }, { "name": "Usual Care", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2021-01-23", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2023-10-23", "last_synced_at": "2026-07-22T22:55:49.143Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04670445" }, { "nct_id": "NCT04551885", "title": "FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "FT516", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-09-07", "completion_date": "2023-08-11", "has_results": false, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-07-22T22:55:49.143Z", "location_count": 3, "location_summary": "Minneapolis, Minnesota • Hackensack, New Jersey • Houston, Texas", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04551885" }, { "nct_id": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor", "Lymphoma" ], "interventions": [ { "name": "Ad-p53", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MultiVir, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-10-01", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2020-06-09", "last_synced_at": "2026-07-22T22:55:49.143Z", "location_count": 3, "location_summary": "Chicago, Illinois • Morristown, New Jersey", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03544723" }, { "nct_id": "NCT03841110", "title": "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma", "Gastric Cancer", "Colorectal Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "EGFR Positive Solid Tumor", "HER2-positive Breast Cancer", "Hepatocellular Carcinoma", "Small Cell Lung Cancer", "Renal Cell Carcinoma", "Pancreas Cancer", "Melanoma", "NSCLC", "Urothelial Carcinoma", "Cervical Cancer", "Microsatellite Instability", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "FT500", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "IL-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fate Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2019-02-15", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2023-05-01", "last_synced_at": "2026-07-22T22:55:49.143Z", "location_count": 4, "location_summary": "San Diego, California • Minneapolis, Minnesota • Hackensack, New Jersey + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03841110" }, { "nct_id": "NCT04272034", "title": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "MSI-H/dMMR Tumors", "Cutaneous Squamous Cell Carcinoma", "Urothelial Carcinoma, HCC", "Cervical Cancer", "Esophageal Squamous Cell Carcinoma", "Merkel Cell Carcinoma", "Small-cell Lung Cancer", "Mesothelioma", "PD-L1 Amplified Tumor (9p24.1)", "Nasopharyngeal Carcinoma", "Cyclin-dependent Kinase 12 Mutated Tumors", "Basal Cell Carcinoma (Unresectable or Metastatic)", "Sarcomatoid Renal Cell Carcinoma", "Clear Cell Ovarian or Endometrial Carcinoma", "Anal Carcinoma", "Squamous Cell Penile Carcinoma", "DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)" ], "interventions": [ { "name": "INCB099318", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 105, "start_date": "2021-03-26", "completion_date": "2024-08-16", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-07-22T22:55:49.143Z", "location_count": 3, "location_summary": "Hackensack, New Jersey • Greenville, South Carolina • Nashville, Tennessee", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04272034" } ] }